* Cocrystal Pharma Inc COCP.OQ COCP.O is expected
to show a
rise in quarterly revenue when it reports results on November
14 (estimated).
* The Bothell Washington-based company is expected to
report
revenue of $83.33 thousand, according to the mean estimate from
3 analysts, based on Refinitiv data.
* Refinitiv's mean analyst estimate for Cocrystal Pharma
Inc is
for a loss of 48 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Cocrystal
Pharma
Inc is $42, above its last closing price of $2.75.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Jun. 30 2022 -0.54 -0.52 -3.00 Missed -477
Mar. 31 2022 -0.36 -0.42 -0.48 Missed -14.3
Dec. 31 2021 -0.48 -0.48 -0.48 Met 0
Sep. 30 2021 -0.48 -0.48 -0.48 Met 0
Jun. -0.42 -0.42 -0.48 Missed -14.3
30 2021
Mar. 31 2021 -0.60 -0.54 -0.48 Beat 11.1
Dec. 31 2020 -0.48 -0.24 Beat 50
Sep. 30 2020 -0.60 -0.60 Met 0
This summary was machine generated November 11 at 17:50 GMT.
All figures in US dollars unless otherwise stated